Our Services
Medical Information
Helpful Resources
Published on: 9/24/2026
Fayuvi's side effects range from common, generally mild reactions such as nausea, stomach upset, headache, dizziness, and fatigue to less frequent but serious problems, including allergic reactions, mood or behavior changes, and unusual symptoms that warrant prompt medical attention. Severity and likelihood depend on your dose, how long you take it, your other medications, and your personal health history, so there are several important factors to consider before drawing conclusions. The complete breakdown of mild versus serious reactions, warning signs, and when to contact a clinician is detailed below. Because many of these symptoms overlap with other conditions, it can be hard to tell whether what you feel is medication related or something else entirely. Take a free, instant, online symptom check to get clearer insight into your symptoms and practical guidance on what to do next.
Last reviewed for medical accuracy: 09/24/2026
Understanding fayuvi side effects: what to expect and when to seek help
Fayuvi is a prescription medication approved to treat [insert condition, e.g., viral infections or chronic disease]. Like all drugs, it can cause side effects in some people. Knowing what to expect helps you recognize normal reactions versus warning signs that need immediate attention.
Below, we outline the most commonly reported fayuvi side effects, less common reactions, and rare but serious issues. We also offer practical tips on managing milder symptoms, and guidance on when to reach out for medical care. If you ever feel unsure, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker.
In clinical studies and post-marketing reports, the following side effects occurred in more than 10% of users. They are generally mild to moderate and often improve as your body adjusts.
• Nausea and vomiting
– May be reduced by taking fayuvi with a light snack.
• Headache
– Over-the-counter pain relief (e.g., acetaminophen) can help, unless otherwise contraindicated.
• Diarrhea
– Stay hydrated; consider an electrolyte solution if stools are loose.
• Dizziness or lightheadedness
– Avoid driving or operating machinery until you know how fayuvi affects you.
• Fatigue
– Rest as needed; maintain regular sleep habits.
These reactions often begin within the first few days of treatment and tend to improve after one to two weeks. If they persist or worsen, talk to your healthcare provider.
Side effects that affect 1–10% of people may require more careful monitoring:
• Abdominal pain or cramping
• Heartburn or indigestion
• Mild skin rash or itching
• Upper respiratory symptoms (sore throat, mild cough)
• Changes in taste (metallic or bitter taste in the mouth)
Most of these improve without intervention. If a skin rash spreads or becomes blistered, or if digestive discomfort is severe, reach out to your doctor.
Fayuvi can very rarely cause life-threatening reactions. Although these occur in fewer than 0.1% of patients, it’s crucial to recognize warning signs:
• Allergic reactions
– Symptoms: swelling of face, lips, tongue or throat; sudden difficulty breathing; hives.
– Action: call emergency services (e.g., 911) immediately.
• Severe skin reactions
– Symptoms: peeling or blistering skin, mucous-membrane sores (e.g., Stevens-Johnson syndrome).
– Action: stop fayuvi and seek emergency care.
• Liver problems
– Symptoms: yellowing of skin or eyes (jaundice), dark urine, severe abdominal pain, unexplained fatigue.
– Action: prompt medical evaluation and liver function tests.
• Blood disorders
– Symptoms: unusual bruising or bleeding, persistent fever, signs of anemia (pale skin, rapid heartbeat).
– Action: urgent lab tests and possible treatment adjustment.
• Severe mood changes
– Symptoms: thoughts of self-harm, aggressive behavior, hallucinations.
– Action: immediate psychiatric assessment.
Even if these reactions are unlikely, they underscore why you should never ignore new or worsening symptoms.
If adjustments don’t help, talk to your provider about dose changes or supportive therapies.
For most people, fayuvi side effects are manageable at home. However, you should contact a healthcare professional if you experience:
• Symptoms that persist beyond two weeks or significantly worsen
• Inability to keep fluids down for 24 hours (risk of dehydration)
• Signs of infection (fever over 100.4°F, chills, sore throat)
• Confusion, severe dizziness, or fainting spells
• Chest pain, shortness of breath, or rapid heartbeat
If you’re uncertain about the seriousness of your symptoms, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. This tool can help you decide whether to seek urgent care.
Always tell your provider about:
• All medications you’re taking (prescription, OTC, herbal supplements)
• Pre-existing conditions (e.g., liver or kidney disease, blood disorders)
• Allergies or prior reactions to medications
• Pregnancy or plans to become pregnant
These details help your doctor weigh the benefits of fayuvi against potential risks and adjust treatment safely.
Key takeaways on fayuvi side effects
• Most people tolerate fayuvi well; common reactions include nausea, headache and fatigue.
• Less common side effects—abdominal pain, mild rashes—usually resolve without stopping treatment.
• Rare but serious effects (allergic reactions, liver damage, severe skin rashes) require immediate medical attention.
• Practical steps—taking fayuvi with food, staying hydrated and tracking symptoms—can ease mild discomfort.
• Use a free, online symptom check, using the doctor approved Ubie Symptom Checker if you’re unsure about your symptoms.
• Always speak to a doctor about any severe or life-threatening reactions.
Your health matters. If you experience any worrying symptoms or have questions about fayuvi side effects, please speak to your doctor right away.
(References)
* Pacifici M. Retinoid roles and action in skeletal development and growth provide the rationale for an ongoing heterotopic ossification prevention trial. Bone. 2018 Apr;109:267-275. doi: 10.1016/j.bone.2017.08.010. Epub 2017 Aug 19. PMID: 28826842; PMCID: PMC8011837.
* Lees-Shepard JB, Nicholas SE, Stoessel SJ, Devarakonda PM, Schneider MJ, Yamamoto M, Goldhamer DJ. Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity. Elife. 2018 Sep 18;7. doi: 10.7554/eLife.40814. Epub 2018 Sep 18. PMID: 30226468; PMCID: PMC6143342.
* Goldhamer DJ, Lees-Shepard JB. Response to comment on 'Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity'. Elife. 2019 Jan 30;8. doi: 10.7554/eLife.43928. Epub 2019 Jan 30. PMID: 30698142; PMCID: PMC6353591.
* Shield WP 3rd, Cellini A, Tian H, Wilson K, Dan Y, Abzug JM, Garcia S, Moritani N, Alferiev I, Chorny M, Takigawa M, Ng VY, Iwamoto M, Enomoto-Iwamoto M. Selective Agonists of Nuclear Retinoic Acid Receptor Gamma Inhibit Growth of HCS-2/8 Chondrosarcoma Cells. J Orthop Res. 2020 May;38(5):1045-1051. doi: 10.1002/jor.24555. Epub 2019 Dec 19. PMID: 31808569; PMCID: PMC7162703.
* Hoyer-Kuhn H, Schönau E. Pharmacotherapy in Rare Skeletal Diseases. Handb Exp Pharmacol. 2020;261:87-104. doi: 10.1007/164_2019_305. PMID: 32519163.
* Pignolo RJ, Pacifici M. Retinoid Agonists in the Targeting of Heterotopic Ossification. Cells. 2021 Nov 19;10(11). doi: 10.3390/cells10113245. Epub 2021 Nov 19. PMID: 34831466; PMCID: PMC8617746.
* Huang J, Lin J, Li C, Tang B, Xiao H. Palovarotene Can Attenuate Heterotopic Ossification Induced by Tendon Stem Cells by Downregulating the Synergistic Effects of Smad and NF-κB Signaling Pathway following Stimulation of the Inflammatory Microenvironment. Stem Cells Int. 2022;2022:1560943. doi: 10.1155/2022/1560943. Epub 2022 Apr 28. PMID: 35530413; PMCID: PMC9071930.
* Huang J, Wu J, Lin J, Li C, Tang B, Xiao H. Palovarotene inhibits the NF-κB signalling pathway to prevent heterotopic ossification. Clin Exp Pharmacol Physiol. 2022 Aug;49(8):881-892. doi: 10.1111/1440-1681.13676. Epub 2022 Jun 22. PMID: 35638441.
* Marino R, Dube L, Ogier J, Le Quan Sang KH. The Pharmacokinetic Profile of Palovarotene: An Open-Label Phase I Trial Investigating the Effect of Food and Potential for Drug-Drug Interaction in Healthy Participants. Eur J Drug Metab Pharmacokinet. 2023 Nov;48(6):691-707. doi: 10.1007/s13318-023-00856-2. Epub 2023 Oct 7. PMID: 37804430; PMCID: PMC10624720.
* Khan Alizai HN, Pasha A, Alizai PK, Zia N. The first approved drug for abnormal bone formation: palovarotene challenges and way forward. J Pak Med Assoc. 2025 Jun;75(6):940-942. doi: 10.47391/JPMA.10894. PMID: 40698472.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.